Probiotics: study protocols
141 study groups say how much Probiotics participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from products
90 products in our catalogue print how much Probiotics a serving holds.
Most common: 100 mg to 250 mg, 32% of 90 products.
| Dose per serving | Products |
|---|---|
| 2.5 mg to 5 mg | 17 |
| 5 mg to 10 mg | 1 |
| 10 mg to 25 mg | 9 |
| 25 mg to 50 mg | 12 |
| 50 mg to 100 mg | 14 |
| 100 mg to 250 mg | 29 |
| 250 mg to 500 mg | 7 |
| over 500 mg | 1 |
Dose per serving from research
119 study groups in 92 studies say how much Probiotics participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 5 billion CFU to 10 billion CFU, 29% of 119 study groups.
| Daily dose | Study groups |
|---|---|
| 0.05 billion CFU or less | 3 |
| 0.05 billion CFU to 0.1 billion CFU | 5 |
| 0.1 billion CFU to 0.25 billion CFU | 4 |
| 0.25 billion CFU to 0.5 billion CFU | 0 |
| 0.5 billion CFU to 1 billion CFU | 12 |
| 1 billion CFU to 2.5 billion CFU | 13 |
| 2.5 billion CFU to 5 billion CFU | 7 |
| 5 billion CFU to 10 billion CFU | 35 |
| 10 billion CFU to 25 billion CFU | 24 |
| 25 billion CFU to 50 billion CFU | 6 |
| 50 billion CFU to 100 billion CFU | 1 |
| 100 billion CFU to 250 billion CFU | 3 |
| over 250 billion CFU | 6 |
Commonly used together
37 of 141 study groups took Probiotics with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Prebiotics | 10 |
| Inulin | 5 |
| Fish Oil | 3 |
| Lactoferrin | 3 |
141 study groups
| Study | |||
|---|---|---|---|
| Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy 2010 · treatment group · Women in the last month of pregnancy and their infants aged 0–6 months | 10 billion CFU | 26 weeks | 220 |
| [A multicenter randomized controlled study of Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in infants and young children] 2017 · prevention group · Hospitalized children aged 1 month to 3 years with non-gastrointestinal infections requiring antibiotic therapy | 250 mg | — | 213 |
| Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial 2017 · HN001 · Pregnant women enrolled at 14–16 weeks’ gestation; participants were eligible if they or the unborn child’s biological father had a history of asthma, hayfever or eczema requiring medication. | 6 billion CFU | — | 212 |
| Effect of Lactobacillus rhamnosus Probiotic in Early Pregnancy on Plasma Conjugated Bile Acids in a Randomised Controlled Trial 2021 · HN001 group · Pregnant women recruited at 14–16 weeks’ gestation whose own or unborn child’s biological father had a history of asthma, hay fever, or eczema requiring medication | 6 billion CFU | — | 212 |
| [Multicenter, randomized, controlled clinical trial on preventing antibiotic-associated diarrhea in children with pneumonia using the live Clostridium butyricum and Bifidobacterium combined Powder] 2012 · treatment group · Hospitalized children aged 3 months to 3 years with pneumonia | 5 billion CFU | 7 days | 193 |
| Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study 2014 · high-dose · Adult hospital in-patients requiring antibiotic therapy; age and sex ranges not reported | 17 billion CFU | — | 168 |
| Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study 2014 · low-dose · Adult hospital in-patients requiring antibiotic therapy; age and sex ranges not reported | 4.17 billion CFU | — | 168 |
| Effect of Limosilactobacillus reuteri DSM17938 to prevent antibiotic-associated diarrhea in children: prospective, multi-center, randomized, placebo-controlled clinical trial (PEARL Study) 2025 · Group 1a (14 days) · Children aged 6 months to 10 years with acute otitis media or acute rhinosinusitis receiving amoxicillin-clavulanate | 0.2 billion CFU | 2 weeks | 168 |
| Effect of Limosilactobacillus reuteri DSM17938 to prevent antibiotic-associated diarrhea in children: prospective, multi-center, randomized, placebo-controlled clinical trial (PEARL Study) 2025 · Group 1b (21 days) · Children aged 6 months to 10 years with acute otitis media or acute rhinosinusitis receiving amoxicillin-clavulanate | 0.2 billion CFU | 3 weeks | 162 |
| Oxygen-driven nebulization of Clostridium butyricum prevents drug-resistant bacterial pneumonia 2026 · Control group · Patients aged 6–85 years with chronic respiratory disease and a history of multiple infections with drug-resistant bacteria | 0.0063 billion CFU | 13 days | 155 |